Literature DB >> 31964645

Original Antigenic Sin: How Original? How Sinful?

Jonathan W Yewdell1, Jefferson J S Santos1.   

Abstract

We review the phenomenon of "original antigenic sin" (OAS) in antibody responses to influenza A virus (IAV) infection or vaccination. OAS refers to the preferential induction of antibodies with higher affinity to priming versus boosting immunogens. We emphasize its mechanistic basis and origins in the basic immunobiology of B-cell responses to myriad immunogens. We tabulate 23 studies in animals and humans to show that the magnitude of OAS depends on many variables. We discuss a number of misconceptions about OAS, examine the extent to which OAS is sinful, and argue that OAS is evolutionary selected and not a deleterious by-product of selection for other features of the immune response. We end by raising questions regarding the mechanistic basis of OAS whose answers could contribute to improving influenza virus vaccines on the road to the holy grail of a "universal" influenza vaccine.
Copyright © 2021 Cold Spring Harbor Laboratory Press; all rights reserved.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 31964645      PMCID: PMC8091961          DOI: 10.1101/cshperspect.a038786

Source DB:  PubMed          Journal:  Cold Spring Harb Perspect Med        ISSN: 2157-1422            Impact factor:   6.915


  16 in total

Review 1.  Subdominance in Antibody Responses: Implications for Vaccine Development.

Authors:  Gunnar Lindahl
Journal:  Microbiol Mol Biol Rev       Date:  2020-11-25       Impact factor: 11.056

2.  Seasonal coronavirus-specific B cells with limited SARS-CoV-2 cross-reactivity dominate the IgG response in severe COVID-19.

Authors:  Muriel Aguilar-Bretones; Brenda M Westerhuis; Matthijs P Raadsen; Erwin de Bruin; Felicity D Chandler; Nisreen Ma Okba; Bart L Haagmans; Thomas Langerak; Henrik Endeman; Johannes Pc van den Akker; Diederik Ampj Gommers; Eric Cm van Gorp; Corine H GeurtsvanKessel; Rory D de Vries; Ron Am Fouchier; Barry Hg Rockx; Marion Pg Koopmans; Gijsbert P van Nierop
Journal:  J Clin Invest       Date:  2021-11-01       Impact factor: 14.808

3.  Bivalent H1 and H3 COBRA Recombinant Hemagglutinin Vaccines Elicit Seroprotective Antibodies against H1N1 and H3N2 Influenza Viruses from 2009 to 2019.

Authors:  James D Allen; Ted M Ross
Journal:  J Virol       Date:  2022-03-15       Impact factor: 6.549

4.  Clonal analysis of immunodominance and cross-reactivity of the CD4 T cell response to SARS-CoV-2.

Authors:  Jun Siong Low; Daniela Vaqueirinho; Federico Mele; Federica Sallusto; Antonino Cassotta; Mathilde Foglierini; Josipa Jerak; Michela Perotti; David Jarrossay; Sandra Jovic; Laurent Perez; Rosalia Cacciatore; Tatiana Terrot; Alessandra Franzetti Pellanda; Maira Biggiogero; Christian Garzoni; Paolo Ferrari; Alessandro Ceschi; Antonio Lanzavecchia
Journal:  Science       Date:  2021-05-18       Impact factor: 47.728

5.  Single-cell BCR and transcriptome analysis after influenza infection reveals spatiotemporal dynamics of antigen-specific B cells.

Authors:  Nimitha R Mathew; Jayalal K Jayanthan; Ilya V Smirnov; Jonathan L Robinson; Hannes Axelsson; Sravya S Nakka; Aikaterini Emmanouilidi; Paulo Czarnewski; William T Yewdell; Karin Schön; Cristina Lebrero-Fernández; Valentina Bernasconi; William Rodin; Ali M Harandi; Nils Lycke; Nicholas Borcherding; Jonathan W Yewdell; Victor Greiff; Mats Bemark; Davide Angeletti
Journal:  Cell Rep       Date:  2021-06-22       Impact factor: 9.995

Review 6.  HLA, Immune Response, and Susceptibility to COVID-19.

Authors:  Fataneh Tavasolian; Mohsen Rashidi; Gholam Reza Hatam; Marjan Jeddi; Ahmad Zavaran Hosseini; Sayed Hussain Mosawi; Elham Abdollahi; Robert D Inman
Journal:  Front Immunol       Date:  2021-01-08       Impact factor: 7.561

Review 7.  Know your enemy or find your friend?-Induction of IgA at mucosal surfaces.

Authors:  Mats Bemark; Davide Angeletti
Journal:  Immunol Rev       Date:  2021-07-30       Impact factor: 10.983

8.  [Possible effect of the "original antigenic sin" in vaccination against new variants of SARS-CoV-2].

Authors:  J Reina
Journal:  Rev Clin Esp       Date:  2021-06-05       Impact factor: 1.556

Review 9.  Factors in B cell competition and immunodominance.

Authors:  Robert K Abbott; Shane Crotty
Journal:  Immunol Rev       Date:  2020-06-01       Impact factor: 10.983

Review 10.  Understanding Antibody Responses in Early Life: Baby Steps towards Developing an Effective Influenza Vaccine.

Authors:  Elene A Clemens; Martha A Alexander-Miller
Journal:  Viruses       Date:  2021-07-17       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.